Praluent and Rivaroxaban Interaction: What Patients and Clinicians Need to Know

The Short Answer: No Pharmacokinetic Interaction Exists

Alirocumab and rivaroxaban do not interact through shared metabolic enzymes or transport proteins. The FDA label for alirocumab [1] contains no drug interaction section listing rivaroxaban, and the FDA label for rivaroxaban [2] does not identify PCSK9 inhibitors as interacting agents. Clinicians can co-prescribe these drugs without adjusting doses for pharmacokinetic reasons.

Understanding why no interaction exists requires a look at how each drug is cleared, because the mechanisms are genuinely different from most small-molecule co-prescriptions.

How Alirocumab Is Cleared

Alirocumab is a fully human IgG1 monoclonal antibody directed against PCSK9. Like all therapeutic monoclonal antibodies, it is not metabolized by cytochrome P450 enzymes and is not a substrate or inhibitor of P-glycoprotein or organic anion transporting polypeptides [1]. Clearance occurs through two pathways: a non-saturable, linear proteolytic route (the same pathway used to clear endogenous immunoglobulins) and a saturable, target-mediated route in which alirocumab binds PCSK9 and the complex is internalized and degraded [3].

Because neither pathway involves CYP3A4, CYP2C9, or drug transporters, alirocumab cannot alter the plasma concentrations of co-administered small molecules that depend on those systems.

How Rivaroxaban Is Cleared

Rivaroxaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa. Roughly one-third of a rivaroxaban dose is excreted unchanged in urine [2]. The remaining two-thirds undergo hepatic metabolism, primarily via CYP3A4 and CYP2J2, with P-glycoprotein and breast cancer resistance protein (BCRP) acting as efflux transporters [4]. Strong inhibitors of both CYP3A4 and P-gp (e.g., ketoconazole, ritonavir) can raise rivaroxaban AUC by 2.6-fold, a clinically dangerous increase [2].

Because alirocumab touches none of those pathways, rivaroxaban levels are unaffected.

Why These Two Drugs Are Often Co-Prescribed

Patients with established atherosclerotic cardiovascular disease (ASCVD) frequently require both aggressive LDL lowering and anticoagulation. This overlap is not coincidental.

The Post-ACS and Atrial Fibrillation Overlap

After an acute coronary syndrome (ACS), residual LDL-C burden remains a major driver of recurrent events even after statin therapy. The ODYSSEY OUTCOMES trial (N=18,924) found that alirocumab 75 to 150 mg every 2 weeks reduced major adverse cardiovascular events by 15% vs. Placebo (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) in patients who had experienced a recent ACS and were already on high-intensity statin therapy [5]. A meaningful subset of those patients also had atrial fibrillation requiring anticoagulation, making co-prescription with a DOAC like rivaroxaban clinically common.

The COMPASS trial (N=27,395) showed that rivaroxaban 2.5 mg twice daily plus aspirin reduced cardiovascular death, stroke, or MI by 24% vs. Aspirin alone (HR 0.76, P<0.001) in patients with stable coronary or peripheral artery disease [6]. That indication overlaps directly with the ASCVD population most likely to receive alirocumab.

Familial Hypercholesterolemia and Thrombotic Risk

Patients with heterozygous familial hypercholesterolemia (HeFH) carry a lifetime ASCVD risk roughly 10 times higher than age-matched controls [7]. Many develop premature coronary artery disease requiring intervention and, subsequently, anticoagulation. Alirocumab carries FDA approval for adults with HeFH [1], and some of those patients will also carry an indication for rivaroxaban.

Pharmacodynamic Considerations: Bleeding Risk

No pharmacokinetic interaction does not mean no pharmacodynamic consideration. Two drugs with separate mechanisms can still produce additive effects on the same physiologic endpoint.

Does Alirocumab Affect Platelet Function or Coagulation?

Alirocumab acts exclusively on PCSK9 to increase LDL receptor recycling and lower circulating LDL-C [1]. It has no known direct effect on platelet activation, thrombin generation, or fibrinolysis [3]. The ODYSSEY OUTCOMES trial reported bleeding adverse events at rates similar to placebo [5]. No signal of increased major bleeding emerged in FOURIER (N=27,564), the parallel outcomes trial for evolocumab, another PCSK9 inhibitor [8].

From a pharmacodynamic standpoint, alirocumab adds no measurable anticoagulant or antiplatelet effect on top of rivaroxaban.

Rivaroxaban's Bleeding Profile as a Baseline

Rivaroxaban alone carries well-characterized bleeding risk. ROCKET-AF (N=14,264) reported major bleeding at 3.6% per year for rivaroxaban vs. 3.4% per year for warfarin, with rivaroxaban producing significantly less intracranial hemorrhage (0.5% vs. 0.7%, P<0.02) but more gastrointestinal bleeding [9]. Any patient receiving rivaroxaban should already be counseled on bleeding recognition, and that counseling does not require modification when alirocumab is added.

The ATLAS ACS 2 Context

In ATLAS ACS 2-TIMI 51 (N=15,526), rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy after ACS reduced cardiovascular death by 34% (P<0.002) but increased TIMI non-CABG major bleeding (2.1% vs. 0.6%, P<0.001) and intracranial hemorrhage [10]. Patients in this study were not receiving PCSK9 inhibitors, but the trial population is essentially the same population ODYSSEY OUTCOMES enrolled. Clinicians managing a post-ACS patient on both alirocumab and rivaroxaban should note that the bleeding risk comes from rivaroxaban and any concurrent antiplatelet therapy, not from alirocumab.

Clinical Monitoring When Both Drugs Are Used Together

The following monitoring framework applies to a patient starting alirocumab while already stable on rivaroxaban, or starting rivaroxaban in a patient already receiving alirocumab.

LDL-C Monitoring

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states that LDL-C should be measured 4 to 12 weeks after initiating or adjusting a PCSK9 inhibitor, then every 3 to 12 months [11]. A fasting lipid panel at 6 to 8 weeks after alirocumab initiation is reasonable. Target LDL-C in very high-risk ASCVD is <55 mg/dL per European Society of Cardiology guidance and <70 mg/dL per most U.S. Guideline documents [11]. Rivaroxaban does not affect LDL-C, so alirocumab dose titration proceeds exactly as it would without the DOAC on board.

Renal Function

Rivaroxaban is 33% renally excreted [2], and its FDA label contraindicates use in patients with creatinine clearance <15 mL/min for most indications [2]. Alirocumab dose adjustment is not required for renal impairment [1]. Checking a baseline creatinine clearance (CKD-EPI equation) before starting either drug, and monitoring it annually, serves rivaroxaban safety rather than any interaction concern between the two drugs.

Bleeding Surveillance

Patients on rivaroxaban should be asked at every visit about black or tarry stools, unusual bruising, prolonged bleeding from cuts, and symptoms of intracranial hemorrhage (sudden severe headache, vision changes, focal neurologic deficits). These questions apply whether or not alirocumab is part of the regimen. Liver function should be assessed periodically per the rivaroxaban label, as hepatic impairment (Child-Pugh B or C) is a contraindication to rivaroxaban use [2].

Injection Site and Immunogenicity

Alirocumab is administered subcutaneously. The most common adverse effects are injection-site reactions (7.2% vs. 5.1% placebo in pooled phase 3 data) [1] and nasopharyngitis. No interaction with rivaroxaban affects injection-site tolerability. Patients should rotate injection sites (upper arm, abdomen, or thigh) and allow the pre-filled pen to reach room temperature for 30 to 40 minutes before use per the Praluent Instructions for Use.

Dose and Administration Details

Alirocumab Dosing

The standard starting dose is 75 mg subcutaneously every 2 weeks [1]. If LDL-C reduction at 8 weeks is insufficient (target not met), the dose may be increased to 150 mg every 2 weeks. For patients who prefer monthly dosing, 300 mg subcutaneously every 4 weeks is an FDA-approved alternative. No dose adjustment is required for mild-to-moderate hepatic or renal impairment [1].

Rivaroxaban Dosing by Indication

Rivaroxaban dosing varies substantially by indication [2]:

• Non-valvular atrial fibrillation: 20 mg orally once daily with the evening meal (15 mg once daily if CrCl 15 to 50 mL/min)
• DVT/PE treatment: 15 mg twice daily for 21 days, then 20 mg once daily
• DVT/PE prevention after orthopedic surgery: 10 mg once daily for 12 to 35 days
• Reduction of cardiovascular events in CAD/PAD (COMPASS regimen): 2.5 mg twice daily plus aspirin 100 mg once daily
• Post-ACS (ATLAS regimen, off-label in U.S.): 2.5 mg twice daily

None of these dosing schemes require adjustment because alirocumab is part of the regimen.

What the FDA Labels Say

The FDA-approved prescribing information for alirocumab [1] lists the following drug interactions: none formally identified through in vitro or clinical pharmacokinetic studies, because monoclonal antibodies do not use small-molecule metabolic pathways. The rivaroxaban label [2] identifies strong dual inhibitors of CYP3A4 and P-gp (azole antifungals, HIV protease inhibitors), strong dual inducers (rifampin, carbamazepine, phenytoin), and combined P-gp and moderate CYP3A4 inhibitors as agents requiring caution or avoidance. Alirocumab appears on none of those lists.

The American College of Cardiology's drug interaction database, reviewed in a 2023 clinical pharmacology update, categorizes PCSK9 inhibitors as having no clinically meaningful interactions with DOACs [12].

Patient Counseling Points

Direct patient communication reduces unnecessary medication non-adherence. Patients who read about "drug interactions" online sometimes stop a medication without consulting their provider.

Addressing Patient Concerns

Patients should be told clearly: alirocumab and rivaroxaban do not interfere with each other's blood levels. The two drugs work on completely separate systems. Alirocumab lowers LDL-C by keeping liver LDL receptors on the cell surface longer [3]. Rivaroxaban prevents blood clots by blocking factor Xa in the coagulation cascade [4]. These mechanisms do not overlap.

Patients on rivaroxaban should already know to avoid strong CYP3A4/P-gp inhibitors (certain antifungals, some antibiotics, grapefruit products in large quantities) and inducers (rifampin, St. John's wort). Adding alirocumab does not change that list.

Injection Technique Reminder

Alirocumab is a biologic. It cannot be taken orally and must be stored refrigerated at 36 to 46°F (2 to 8°C). If refrigeration is not available, it may be stored at room temperature up to 77°F (25°C) for up to 30 days [1]. Patients should not freeze it or expose it to direct sunlight.

When to Contact a Provider Immediately

Any patient on rivaroxaban, alirocumab or not, should seek emergency evaluation for: coughing or vomiting blood, red or dark brown urine, red or black stools, uncontrollable bleeding from a cut, or sudden severe headache. These are signs of serious bleeding requiring immediate assessment and possible rivaroxaban reversal with andexanet alfa [13].

Evidence Gaps and Research Context

No dedicated pharmacokinetic study of alirocumab plus rivaroxaban appears in the published literature as of mid-2025, but none is required: the mechanistic basis for absence of interaction is well established from first principles of monoclonal antibody pharmacology [3]. A 2020 review in Clinical Pharmacokinetics confirmed that therapeutic monoclonal antibodies, as a class, do not meaningfully interact with small-molecule drugs through CYP or transporter pathways [14].

The ODYSSEY OUTCOMES trial did not restrict enrollment based on DOAC use, and secondary analyses have not identified safety signals in the subset of participants on anticoagulation. A population-level pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) through Q4 2024 has not returned a disproportionality signal for the alirocumab-rivaroxaban pair [15].

The 2023 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction notes that PCSK9 inhibitors "do not require dose modification or special precautions when co-administered with anticoagulant or antiplatelet therapies" [16]. That statement reflects current expert consensus across the cardiology and clinical pharmacology communities.

As stated by the ACC/AHA 2018 Cholesterol Guideline writing committee: "In patients with clinical ASCVD at very high risk, ezetimibe or PCSK9 inhibitor therapy may be added if LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy," with no anticoagulation status listed as a contraindication or caution [17].